Subgroups according to BASDAI/ASDAS category (baseline)
Por um escritor misterioso
Descrição
Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial - Fabian Proft, Anja Weiß, Murat Torgutalp, Mikhail Protopopov, Valeria Rios Rodriguez, Hildrun
Moxibustion for ankylosing spondylitis: A systematic review and meta-analysis - ScienceDirect
Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis
Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis
NNTs vs. placebo for various thresholds of improvement in BASDAI from
Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central–eastern Europe
Frontiers Correlation Between Chronic Pain Acceptance and Clinical Variables in Ankylosing Spondylitis and Its Prediction Role for Biologics Treatment
Baseline values and 3-month response in subgroups according to CRP
Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of
de
por adulto (o preço varia de acordo com o tamanho do grupo)
